Symvess Sales Reach $0.5M as Humacyte Secures $1.475M Saudi Commitment
HUMA•Humacyte posted first-quarter Symvess sales of $0.5M versus $0.1M a year earlier and secured a $1.475M purchase commitment in Saudi Arabia. It appointed Jim Mercadante as CCO, cut $14.3M spending and 25% headcount, and awaits Phase 3 hemodialysis access results on June 11.
1. Financial Results
Humacyte recorded first-quarter revenues of $0.5M from Symvess sales, a fivefold increase from $0.1M in Q1 2025. The quarter also included a minimum $1.475M purchase commitment for Symvess clinical evaluation in Saudi Arabia.
2. Leadership Appointments
The company named James Mercadante as Chief Commercial Officer to oversee sales, marketing and market access, and appointed Dr. Todd Rasmussen as Chief Surgical Officer to guide scientific strategy and clinician education.
3. Commercial and Regulatory Updates
Its Marketing Authorization Application for Symvess vascular injury repair was accepted for review by the Israel Ministry of Health with a 180-working-day timeline. Additionally, the U.S. Department of Defense allocated funding for procurement of bioengineered blood vessels.
4. Cost Cuts and Upcoming Milestones
Humacyte reduced 2026 spending by $14.3M and cut headcount by approximately 25% to focus on commercialization and late-stage trials. Top-line interim results from the Phase 3 hemodialysis access study are expected on June 11, with Phase 1/2 coronary bypass trial planned for H2 2026.
